B+
Bull case
20%
Probability
Target price
$3.50
Analysis reference price unavailable
Analysis 2026-09-06 · RankAlpha Sentiment Codex
ALDX
Aldeyra TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Regulatory clarity or a credible resubmission path for reproxalap could re-rate the shares, while the RASP pipeline and projected runway provide longer-term optionality. The ADX-629 data were positive but based on a small exploratory study.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Clinical and regulatory execution risk across next-generation RASP programs.
Momentum
35
Value
41
Sentiment
95
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.60 · Bull $3.50 · Bear $0.60Analysis 2026-09-06; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-06 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $6.60
Why
Momentum35 · Δ7d -
Value41 · Δ7d -0.0
Sentiment95 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • Clinical and regulatory execution risk across next-generation RASP programs.
- • Loose peer set and unavailable analyst-revision, options, short-interest, and social-coverage data limit confidence in relative valuation and positioning.
- • The FDA rejection leaves Aldeyra without a clear near-term approval or commercialization path.
Catalyst clock
2026-12-05
FDA interaction and potential resubmission plan
Lead driver: Sentiment · See AI snapshot
Momentum
35
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
95
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 35.1 / Value 41.2 / Sentiment 94.9
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-06. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$1.60
Analysis reference price unavailable
Analysis 2026-09-06 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.60
Analysis reference price unavailable
Analysis 2026-09-06 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$94.11M
Beta
0.98
Shares Out
60.33M
P/E (TTM) · Derived
-2.8
P/S (TTM)
-
P/FCF (TTM) · Derived
-4.26
Rev YoY
-
EPS YoY
-44.4%
Gross Margin
-
Op Margin
-
Net Debt
-$54.51M
Current Ratio
4.84
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data